(Q37978967)

26 August 2017

title

Present status and perspectives in functional analysis of p53 in chronic lymphocytic leukemia (English)

1 reference

26 August 2017

0 references

1 reference

Emeline de Viron

1

1 reference

26 August 2017

Lucienne Michaux

2

1 reference

26 August 2017

Natalie Put

3

1 reference

26 August 2017

Françoise Bontemps

4

1 reference

26 August 2017

Eric Van Den Neste

5

1 reference

26 August 2017

publication date

1 March 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

53

1 reference

26 August 2017

issue

8

1 reference

26 August 2017

page(s)

1445-1451

1 reference

Chronic lymphocytic leukemia

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Update on therapy of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

State of the art treatment of chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

p53 as a predictor for chemotherapy response in CLL cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Understanding and managing ultra high-risk chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

21 January 2018

Modes of p53 regulation

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Mdm2 links genotoxic stress and metabolism to p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

p53-mediated activation of miRNA34 candidate tumor-suppressor genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Transcriptional control of human p53-regulated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Transcriptional regulation by p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Tumor suppressor p53 meets microRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

DNA damage response pathways in tumor suppression and cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

p53: the attractive tumor suppressor in the cancer research field

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Genomic aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Importance of genetics in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

TP53 mutation and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Differential roles of STAT1alpha and STAT1beta in fludarabine-induced cell cycle arrest and apoptosis in human B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Basic fibroblast growth factor suppresses p53 activation in the neoplastic cells of a proportion of patients with chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

miR-34a repression of SIRT1 regulates apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

A novel type of p53 pathway dysfunction in chronic lymphocytic leukemia resulting from two interacting single nucleotide polymorphisms within the p21 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Glycogen synthase kinase 3beta phosphorylates p21WAF1/CIP1 for proteasomal degradation after UV irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Nucleoside analogs induce proteasomal down-regulation of p21 in chronic lymphocytic leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic Leukemia once treatment is initiated.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

The role of Bcl-2 family proteins in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

DNA damage checkpoint control in cells exposed to ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Type II topoisomerases--inhibitors, repair mechanisms and mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Molecular mechanisms of ultraviolet radiation-induced DNA damage and repair

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Nucleoside analogs: molecular mechanisms signaling cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to MDM2 inhibitor-mediated apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

21 January 2018

Surfing the p53 network

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

High frequency of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia patients using the VH3-21 gene segment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.660630

10.3109/10428194.2012.660630

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference